C4 Therapeutics (C4T) has announced a collaboration with Roche to develop degrader-antibody conjugates (DACs) targeting two undisclosed oncology indications, with an option for a third. This partnership aims to leverage C4T’s TORPEDO® platform for designing highly catalytic and selective degrader payloads, while Roche will focus on antibody selection and conjugation. The agreement includes a $20 million upfront payment to C4T, with potential milestone payments exceeding $1 billion for discovery, development, and commercialization, alongside tiered royalties on future sales.

This collaboration is significant as it combines targeted protein degradation (TPD) with traditional antibody-drug conjugates (ADCs), which have faced limitations due to narrow therapeutic margins. DACs promise to enhance therapeutic indices by utilizing catalytic mechanisms unique to degraders, allowing for improved specificity and efficacy in targeting cancer cells. The integration of these two modalities could lead to transformative therapies that address hard-to-treat cancers, potentially overcoming challenges associated with drug resistance and undruggable targets.

The implications of this partnership extend to the broader landscape of cancer therapeutics. By validating the DAC approach, this collaboration may shift research paradigms towards the development of combination therapies that incorporate both ADC and TPD strategies. As C4T and Roche advance their pipeline, this could accelerate timelines for bringing innovative cancer treatments to clinical practice, potentially reshaping the therapeutic options available for patients with limited responses to existing therapies.

Source: globenewswire.com